本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Can-Fite Biopharma Ltd

1.01
-0.0100-0.98%
成交量:7.68万
成交额:7.85万
市值:1,341.08万
市盈率:-0.93
高:1.04
开:1.03
低:1.00
收:1.02
数据加载中...
2025/04/14

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/11/14

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/09/06

SEC问询函

Form CORRESP - Correspondence
2024/04/05

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/03/28

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/02/14

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/01/03

SEC问询函

Form CORRESP - Correspondence
2023/09/11

SEC问询函

Form CORRESP - Correspondence
2023/04/21

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2023/03/30

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/02/10

[修订]招股说明书

F-1/A [Amend] - Registration statement for certain foreign private issuers
2023/02/08

SEC问询函

CORRESP [Cover] - Correspondence
2023/01/31

招股说明书

F-1 - Registration statement for certain foreign private issuers
2022/03/24

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/11

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/04

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/01/13

SEC问询函

CORRESP [Cover] - Correspondence
2021/08/26

招股说明书

Can-Fite BioPharma Ltd.
2021/08/26

招股说明书

F-1 - Registration statement for certain foreign private issuers